Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments Shayam Suseelan and Graziano Pinna
Advances in exosome analysis Arnau Pallares-Rusiñol, Mireia Bernuz, Silio Lima Moura, Carolina Fernández-Senac, Rosanna Rossi, Mercè Martí, and María Isabel Pividori
Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles Xiaofeng Wu, Anton B. Iliuk, and W. Andy Tao
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers Koji Kurose, Kanako Sakaeda, Minoru Fukuda, Yumiko Sakai, Hiroyuki Yamaguchi, Shinnosuke Takemoto, Katsuhiko Shimizu, Takeshi Masuda, Katsumi Nakatomi, Shigeo Kawase, Ryo Tanaka, Takayuki Suetsugu, Keiko Mizuno, Takehiro Hasegawa, Yusuke Atarashi, Yasuhiro Irino, Toshiyuki Sato, Hiromasa Inoue, Noboru Hattori, Eiichiro Kanda, Masao Nakata, Hiroshi Mukae, Toru Oga, and Mikio Oka
Advances in congestive heart failure biomarkers Iyyapu Krishna Mohan, K.S.S. Sai Baba, Rohit Iyyapu, Sunitha Thirumalasetty, and O. Sai Satish
Fluid biomarkers in Alzheimer's disease Joel Simr
Dr Gregory S Makowski is a board certified clinical chemist and fellow of the National Academy of Clinical Biochemistry. Following receipt of his PhD in Biochemistry from the University of Connecticut Storrs, he pursued post-doctoral studies at the University of Connecticut School of Medicine in Farmington that culminated in his joint appointments in the School of Medicine and the Department of Laboratory Medicine at John Dempsey Hospital. He has numerous clinical and basic science publications and serves on various scientific and editorial boards. He is actively engaged in the training of Pathology residents and fellows in the Department of Pathology and Laboratory Medicine at Hartford Hospital. He currently serves as Vice President and Chief Scientific Officer for Clinical Laboratory Partners in Newington CT, USA.